Open AccessMetformin and cancer mortality
Author(s) -
Lev Bershteyn
Publication year - 2010
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-5491
Subject(s) - metformin , medicine , cancer , type 2 diabetes mellitus , oncology , diabetes mellitus , intensive care medicine , endocrinology
The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of DM as a riskfactor of cancer morbidity and mortality, mechanisms and targets of metformin anticancer effects, and potential use of this agent in non-diabetic patientsare discussed. The need for the search of the markers of sensitivity and resistance to metformin to be used in oncological practice is emphasized.